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The mechanism of self-recognition of the autoantigen TROVE2, a common biomarker in 
autoimmune diseases, has been studied with Quartz Crystal Microbalance with 
Dissipation monitoring (QCM-D) and Dual Polarization Interferometry (DPI). The 
complementarity and remarkable analytical features of both techniques has allowed to 
achieve new insights onto the onset of systemic Lupus Erythematosus (SLE) at the 
molecular level. 
The in vitro study for SLE patients and healthy subjects suggests that anti-TROVE2 
autoantibodies may undergo an antibody bipolar bridging. An epitope-paratope specific 
binding initially occurs to activate a hidden Fc-receptor in the TROVE2 tertiary structure. 
This bipolar mechanism may contribute to the pathogenic accumulation of anti-TROVE2 
autoantibody immune complex in autoimmune disease. Furthermore, the specific calcium 
dependent protein-protein bridges point out at how the TRIM21:TROVE2 association 
might occur, suggesting that the TROVE2 protein could stimulate the intracellular 
immune signaling via the TRIM21 PRY-SPRY domain. These findings may help to better 
understand the origins of the specificity and affinity of TROVE2 interactions, which 
might play a key role in the SLE pathogenesis.  
This manuscript gives one of the first practical applications of two novel functions (-
df/dD and h/molec) for the analysis of the data provided by QCM-D and DPI. In 
addition, it is the first time that QCM-D has been used for mapping hidden Fc-receptors 





Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease 
characterized by flares when symptoms arise, and periods of remission when symptoms 
are under control [1]. The disease affects nearly every organ of the human body, mainly 
the skin, heart, lungs and intestines [2]. SLE is one of the most unpredictable, and 
devastating diseases associated with a high morbi-mortality [3].It is also considered the 
prototype systemic autoimmune disease, affecting 40-50 persons per 100,000 with a 9:1 
ratio prevalence female to male [4]. 
SLE is characterized by the over-production of proteins and autoantibodies, whose 
immune complexes induce tissue inflammation and destruction in important organs as the 
kidney and brain. Its clinical manifestation is well known and characterized, however, the 
complex mechanism of on-set is not well understood. There is a strong evidence that it is 
presumably initiated by unknown environmental factors, acting on persons with defects 
in the immune system [5]. For that, patients are being currently treated by a drug -
BENLYSTA® (belimumab)- targeted to inhibit the B-cell activating factor that is 
responsible for part of the normal immune response, and also for the over-aggressive 
immune response. Other drugs are under investigation or never reached the market. 
Nonetheless, the vast majority of therapies have been designed using the same strategy 
that is being employed for other autoimmune diseases with inflammatory components, 
such as rheumatoid arthritis, Inflammatory Bowel Disease, psoriasis, etc. While they are 
quite successful in ameliorating some of the symptoms of these diseases, the biologics 
and small drugs employed are not effective in all patients and, often, have devastating 
side effects. Thus, there is a need for more effective therapies for SLE. Current therapeutic 
agents do not directly target specific pathways for SLE mostly because there is not enough 
information on the nature of the mechanism of the disease at the molecular level. The 
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knowledge of this mechanism is important as it could lead to the design of new targets 
for therapeutic intervention that could result in more specific drugs and better outcomes 
for patients.  
Anti-Ro/SSA autoantibodies are the most prevalent specificity among many autoimmune 
diseases, such as SLE, Sjögren's syndrome, systemic sclerosis, idiopathic inflammatory 
myopathies, rheumatoid arthritis or primary biliary cirrhosis. Among them, the Ro 
ribonucleoprotein complex (Ro/SSA RNP complex) is a major antigen, targeted by 
autoantibodies in patients suffering from SLE [6].It is composed of one of the four small 
cytoplasmic RNAs and at least two proteins; the 60-kDa protein Ro60/TROVE2 and the 
48-kDa phosphoprotein La [7].A third protein of molecular mass 52 kDa (Ro52/TRIM21) 
has also been reported to be associated with this multiprotein, but this association has not 
been proven so far [8].No binding site for TRIM21 has been identified yet, suggesting 
that the association of TRIM21 with Ro should be mediated via interaction with 




In contrast to the well-characterized ribonucleoproteins, the function of the Ro protein 
complex, associated with noncoding RNAs (ncRNAs) has been an enigma for over 30 
years. Rather recently, it has been postulated that the role of the protein complex in 
biological processes might be the same than that played by its respective subunits, i.e., 
the TRIM21 and TROVE2 proteins [11]. 
TROVE2 is a 538 a.a. protein [12] which is an important member of the nuclear antigen 
family and a common biomarker of autoimmune diseases [13]. TROVE2 binds 
synergistically to a sequence of ncRNAs known as YRNAs [14], allowing to constitute a 
stable complex with exoribonuclease polynucleotide phosphorylase, a RNA degradation 
protein [11]. Consequently, the main known function of TROVE2 is to perform a quality 




The human TROVE2 structure has not fully been elucidated, however, two domains of 
the Xenopus laevis (also known as the African claw-toed frog) have been solved [9], 
namely, the Telomerase, Ro and Vault (TROVE) and von Willebrand factor A (vWFA). 
The TROVE domain is a doughnut-shape domain consisting of 7 helical HEAT-like 
repeats [16].The von Willebrand factor A domain is present in a large number of proteins 
involved in cell adhesion such integrins [17]. The vWFA has a metal ion-dependent 
adhesion site (MIDAS) motif (D-x-S-x-S…T…D) where divalent cations can bind, 
rearranging the tertiary structure of the protein and mediating the ligand binding [18].  
Anti-TROVE2 autoantibodies are produced in large amounts by the immune system in 
patients suffering from SLE and can be detected years before the disease manifestation, 
providing with a detection target for early diagnosis of SLE. Epitope mapping studies 
showed that TROVE2 has a conformational epitope between 169-190 a.a. [19]. These 
amino acids reside in a loop involved in binding single-stranded RNA, so anti-TROVE2 
antibodies target a key part for its functional mechanism [11]. Thus, although the 
underlying cause of SLE is not fully defined, it has been hypothesized that it is related to 
the cellular function of the TROVE2 protein [20]. 
Quartz Crystal Microbalance with Dissipation monitoring (QCM-D) has been widely 
used for biosensing, given its remarkable analytical features. However, few studies have 
been carried out using QCM-D together with Dual Polarization Interferometry (DPI), a 
complimentary method to it for measuring the supramolecular conformation of adsorbed 
films [25], another label-free technique which provides real-time results of mass and 
thickness with a very high resolution (0.1 pg/mm2, 0.1 Å ). The joint use of both 
techniques provides important advantages, such as the determination of the mass of water 
within the adlayer, which plays a very important role in biochemical processes. Moreover, 
the use of two novel functions: -df/dD and h/molec, recently reported [24] allows the 
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detection and characterization of reaction intermediates in situ, showing the effect of the 
hydrodynamic flow during the biomolecular interaction. These techniques have never 
previously been used to monitor reaction intermediates in this way. 
In the herein reported study, conformational dynamic studies performed with QCM-D 
and DPI have provided new insights into the mechanism of the on-set of SLE at the 
molecular level. Specifically, we present the origins of specificity and affinity of 
TROVE2 interactions in SLE patients and healthy subjects. Studies of biomolecular 
conformations were performed using a novel methodology to analyze data of QCM-D. 
This technique was used together with DPI [25], another label-free technique which 
provides real-time results of mass and thickness with a very high resolution (0.1 pg/mm2, 
0.1 Å ). Furthermore, QCM-D has been used for the first time to map hidden Fc-receptors 
in the protein tertiary structures, as well as to map linear epitopes. 
The achieved results revealed an antibody bipolar bridging mechanism for the TROVE2-
autoantibody interaction. We discovered that the specific calcium dependent protein-
protein interactions (or bridges) point out how the TRIM21-TROVE2 synergy might 
occur. The results suggested that the chemistry of TROVE2 might play a key role in 
regulating the intracellular immune response, providing a better understanding of the SLE 
disease. We envision that this new information could lead to the design of novel more 
specific therapeutic interventions for SLE. 
MATERIAL AND METHODS 
Ethics Statement. Approval from the Biomedical Research Ethics Committee of La Fe 
Hospital was obtained to conduct this study. All patients agreed to take part in the study 
and for their samples to be stored in La Fe Biobank, and gave their informed written 
consent to be included in the study. All experiments were performed in accordance with 
relevant guidelines and regulations. 
8 
 
Serum Samples. Hundred sixty samples from patients with SLE and eight control 
samples (healthy subjects) were obtained from the Departamento de Reumatología, 
Hospital Universitario y Politécnico La Fe, Valencia (Spain). Blood samples were 
collected by venipuncture of the patient’s forearm vein, and were processed immediately 
after extraction, they were handled by standard procedures and stored at -80°C in La Fe 
Biobank. All patients satisfy the SLICC validated the classification criteria to be 
diagnosed as SLE. To develop a diagnostic for SLE patients at all stages of the disease, 
our calibration serum pool contained samples of fifteen and eight sera from anti-Ro+ 
patients with SLE (anti-Ro > 200 U/mL) and healthy subjects (anti-Ro < 15 U/mL), 
respectively. 
hIgG Purification. Immunoglobulins type G (IgGs) were purified by affinity 
chromatography (GE Healthcare, HiTrapTM protein G HP) following the manufacturer 
protocol. The purified hIgGs were concentrated using ultrafiltration (Pall Corporation, 
Macrosep® Advance Centrifugal Device, 30K MWCO). Finally, the concentration of 
anti-TRIM21 and anti-TROVE2 autoantibodies were quantified by means of human anti-
SSA(Ro-52) and human anti-SSA(Ro-60) ELISA kits (Signosis-Biosignal Capture). The 
optical density of each well was measured using a microplate reader (Wallac, Victor 1420 
multilabel counter) at 450 nm. Biostatistical analysis was performed using the R software 
version 3.2.3. 
Quartz crystal microbalance with dissipation monitoring (QCM-D). QCM-D 
measurements were carried out using commercially available gold Q-sense sensors (5 
MHz, QSX 301, Biolin Scientific). The frequency and dissipation variations were 
monitored using Q-Sense E1 (Biolin Scientific, Sweden) device equipped with a liquid 
flow cell setup. All experiments were carried out in the phosphate buffered saline (1x 
PBS, 10 mM phosphate, 137 mM NaCl, 2.7 mM NaCl, pH 7.4) solution to dissolve 
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protein and the resonance frequency was stabilized in 1x PBS. The flow rate was 50 
µL/min at 25ºC. 
Prior to use, the Q-sense sensors were irradiated at 254 nm for 10 min and heated at 75º 
C with a 5:1:1 mixture of mili-Q water, ammonia (25%) and H2O2 (30%) for 5 min. At 
the end, the sensors were irradiated again for 10 min. 
Self-Assembly Monolayer (SAM). SAM was prepared by treating the quartz crystal with 
10mM of MPA (3-mercaptopropionic acid, Sigma-Aldrich) overnight and then activated 
with 46 mM of EDC -N-ethyl-N’-(3-dimethylaminopropyl) carbodiimide, Sigma-
Aldrich, purum grade-/NHS (N-hydroxysulfosuccin-imide 98%, Sigma-Aldrich) for an 
hour to produce a carboxyl chip. 
Immobilization of C-terminal of protein on hydrazine chip. Hydrazine chip was 
prepared by converting carboxyl group on SAM to hydrazide group by treating with 5 
mM carbohydrazide 98 % (Sigma-Aldrich) before protein immobilization. One hundred 
microliter of TROVE2 (recombinant human RO-60/SS-A expressed in Escherichia coli 
(E. coli), long isoform, ProSpec), or TRIM21 (recombinant human RO-52/SS-A 
expressed in E. coli, Sigma-Aldrich), was added at the dose of 33 mg/L (around 49 
ng/cm2, saturation probe), and incubated for an hour to be cross-linked to the activated 
gold surface via its N-terminal amino group. Uncrosslinked residues were blocked by 1 
M ethanolamine-HCl ≥ 98% (Sigma-Aldrich) and a blocking buffer containing 1 mM 
ethylenediaminetetraacetic acid (Riser), 0.25% bovine serum albumin (BSA, Sigma-
Aldrich, ≥ 98% agarose gel electrophoresis), and 0.05% Tween-20 (Scharlau, synthesis 




Immobilization of N-terminal of polypeptides on carboxyl chip. After above-
mentioned treatment and rinsing with mili-Q-water, 33.3 mg/L of polypeptide sequences 
(peptides&elephants) were added to the chip. Each polypeptide was terminated by an 
amino acid with a free amine group, and an amide group at its C-terminus. Those chips 
were then blocked with 20 mg/mL of D-glucamine 95% (abcr) in 1x PBS, pH 9.75 and 
rinsed with mili-Q water. 
Immobilization steps were characterized by Static Water Contact Angle (SCA), 
Polarization Modulation Infrared Reflection Absorption Spectroscopy (PM-IRRAS) and 
X-ray Photoelectron Spectroscopy (XPS) with a high precision, following the procedures 
reported in a previous manuscript [21]. In all cases, data confirmed the formation of 
hydrophilic SAMs of TROVE2 with a high structural order and surface homogeneity. 
Dual Polarization Interferometry. DPI measurements were carried out by an Analight 
Bio200 Dual Polarization Interferometer (Biolin Scientific, Sweden) consisted of a 
helium neon laser (λ=632.8 nm and 20 mW), a 1024×1024 element-imaging device and 
a sensor chip clamped inside a thermally insulated chamber (temperature control within 
0,27315 ºC). The state of polarization of light was switched on a 2 ms cycle between 
transversal electric and magnetic modes using a ferroelectric crystal, before passing 
through the sensor. The interference pattern formed in the far-field was detected on the 
opposing side by the element-imaging device. Data acquisition and treatment were carried 
out by using Analight DAQ (Biolin) and Analight Explorer (Biolin) software packages, 
respectively. Solutions were flowed by a double-channel precision syringe pump 
(Harvard Apparatus PHD 2000 Infusion, Kent, UK) and the injections were carried out 
by using two high-performance chromatography valves connected in series. During the 
entire experiment the flow was maintained at a constant rate of 20 µL/min, and all 
solutions were injected in volumes of 250 µL. 
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Chip activation. The activation of the DPI chip (FB100, Farfield, UK) was achieved by 
immersing the chip overnight in chromic mixture (100 g/L K2Cr2O7 in 85% H2SO4), the 
chip was then rinsed with deionized water and dried with nitrogen; after that it was 
submerged in 20 % HNO3 for 2 h. After rinsing with deionized water and drying with 
nitrogen the activated chip was immersed in 1% carboxyethyl silanetriol (CEST) for 1 h 
and after cleaning with water it was placed in an oven at 110 °C for 1 h. A 1x PBS solution 
filtered through a 0.45 µm PVDF filter and degassed by sonication was used as carrier. 
That solution was also used to prepare the solutions injected unless otherwise stated. With 
the treated chip mounted on the setup an injection of 0.2 M 3-(3-dimethylaminippropyl)-
carbodiimide (EDC) and 0.05 M N-hydroxysuccinimide (NHS) in water followed by an 
injection of 5 mM of carbohydrazide in water were done. TROVE2 (recombinant human 
RO-60/SS-A expressed in E. coli, long isoform, ProSpec) was then immobilized by 
covalent binding by injecting a 60 mg/L solution of this protein. After that an injection of 
20 g/L of glucamine in 1x PBS (pH 9.75) was performed. Finally, a 300 mg/L solution of 
purified hIgGs from SLE patients sera was injected in one channel and a 300 mg/L 
solution of serum from healthy subjects was injected in the other channel. To study the 
effect of calcium ions on the TRIM21-TROVE2 interaction, a 33 mg/L TRIM21 solution 
was immobilized instead of TROVE2 and a 50 mg/L TROVE2 solution in PBS with Ca2+ 
100 mM was injected instead of sera solutions; 100 mM of Ca2+ was added to the PBS 
used as carrier to perform this injection. 
Assays. Four experimental parameters were measured: the dissipation factor and 
resonance frequency changes, provided by QCM-D, and the variations of mass and 
thickness, provided by DPI. All measurements were performed in triplicate, being their 
reproducibility within 5 to 10% for a measurement rate of 200 data points per second. 
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Consequently, the reported results are based on a high number of experimental data (e.g 
the kinetic parameters were fitted with 80,000 data points).  
On the other hand, as shown in supplementary material, there was a negligible interaction 
between TROVE2 and BSA, Fc fragments and non-specific IgGs, over a wide range of 
concentrations. Furthermore, the control for immobilized BSA with IgG was also zero at 
all concentrations tested. Consequently, it is possible to establish that nonspecific 
interactions were negligible. 
RESULTS 
The experiments performed toward elucidating the mechanism of on-set of SLE shed 
important light into the dynamic interactions of TROVE2 and TRIM21 with other 
molecules such as the SLE autoantibodies. With this aim, we carried out a series of 
experiments employing samples from individuals with SLE and healthy controls. We first 
focused our attention to the formation of the complexes between TROVE2 and the 
autoantibodies. This antigenic complex formation, TROVE2-autoantibodies, was 
followed by QCM-D. For this purpose, recombinant human TROVE2 protein expressed 
in E. coli was immobilized on a gold QCM-D sensor using a hydrophilic self-assembled 
monolayer (SAM) with a high structural order and homogeneity [21]. The surface 
concentration of protein immobilized on the sensor was 194 ng/cm2. 
Antigen-antibody interactions are influenced by the bulk concentration of the protein in 
solution. For that, the change of the surface density of the antigenic complex with anti-
TROVE2 autoantibodies (hIgGs) concentration was studied in a steady state [21].The 
results obtained with the human samples revealed a cooperative binding between the 
autoantigen TROVE2 and the circulating autoantibodies, as well as a different binding 
equilibrium for SLE patients and control subjects. However, it is important to emphasize 
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that the monitored signal was free from unspecific interactions, since the piezoelectric 
response of the negative control, bovine serum albumin (BSA), was negligible for all 
concentrations tested ([50-2,000] mg/L, see Supplementary Figure 1). Furthermore, the 
presence of human Fc-receptors in the TROVE2 protein could be also discarded, given 
that the evolution of the piezoelectric signal was nearly zero when active human antibody 
Fc fragments were flowed through the sensor ([50-2,000] mg/L, see Supplementary 
Figure 2). Consequently, the recognition was only specific with a single epitope-paratope 
binding involved in the TROVE2-hIgG biorecognition. 
Conformational dynamics 
Interactions between proteins and ligands are relevant for regulation of biological 
processes, because intrinsic conformational dynamics of proteins play crucial roles in 
ligand binding and dissociation [22,23].Accordingly, the conformational dynamics of the 
TROVE2 biorecognition was studied here by QCM-D, applying the novel function -∂f/∂D 
(∂f and ∂D are the time derivatives of the frequency and dissipation factor, see 
Supplementary Note 1) [24].This function provides a clear identification of the structural 
transitions of the adsorbed layer and allows the reaction path to be monitored in real time. 
Similarly, Fakhrullin et al. developed a QCM immunosensor with the simultaneous 
measurement of resonance frequency and motional resistance for the detection of 
antibodies to double-stranded DNA [26]. 
As shown in Figure 2a, the -∂f/∂D plot was found to be a peak-shape function with a 
maximum centered at ∼9 Hz for both SLE patients and healthy subjects [21]. 
Consequently, the TROVE2 biorecognition process exhibits similar conformational 
dynamics with two elementary steps because the -∂f/∂D plot is always a peak-shape 
function (Young's modulus of reactive complex, intermediate complex and product 
14 
 
complex). Indeed, comparable -∂f/∂D values were obtained for both intermediate states 
(Int. I and Int. II) and reaction products (PI and PII), suggesting similar structures. Steady-
state data also suggested the formation of antigenic complexes with similar structures, 
since their -∂f/∂D values are very similar (see Supplementary Table 1). 
 
 
In order to get more insights about the TROVE2 biorecognition event, this step was also 
studied by DPI. This label-free technique allows the determination of the thickness and 
dry mass of bound biological molecules on the adlayer in real-time with resolutions of 
0.1 Å and 0.1 pg/mm2, respectively [25].As depicted in Figure 2b, the changes in 
thickness per molecule by means of the novel function h/molec (see Supplementary 
Note 2) for hIgGs showed that the TROVE2-autoantibody interaction involves two and 
one reactive species for SLE patients and control subjects, respectively. Taking into 
account the antibody dimensions, results monitored by DPI suggest that SLE hIgGs 
targeted initially the TROVE2 antigen by only one Fab fragment (≈ 12.2 nm/molecule, 
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Int. Ia). Next, another antibody fragment interacted with the antigen (≈ 13.4 nm/molec, 
PI), being both states connected via a reaction intermediate (≈ 14.0 nm/molec, Int Ib).  
For healthy subjects (Figure 2b), the hIgGs targeted the TROVE2 antigen by a Fab and 
another antibody fragment (≈ 11.4 nm/molecule, PII). In this context, we took advantage 
of the complementarity of the two analytical techniques employed. So, the combination 
of QCM-D results (wet mass) with DPI data (dry mass) allowed us to calculate values of 
the water content of internally trapped water molecules in the protein. Thus, Figures 2a 
and 2b show how the structural changes detected by QCM-D during this biorecognition 
event are more pronounced than those detected by DPI for both SLE and control hIgGs. 
Hence, this binding must mainly involve changes in the structuring of the surrounding 
water by the TROVE2 protein in both cases. As water is a major contributor to the 
protein´s 3D structure the protein hydration shell dynamics might play an important role 
in the TROVE2-hIgG molecular recognition of healthy subjects and SLE patients. 
However, a complete understanding of the TROVE2 functional mechanism requires a 
detailed picture of this hydration dynamics for which modelling studies were performed 
as described below. 
Modelling 
As mentioned above, our results revealed two binding sites and two reaction steps for the 
TROVE2–hIgG molecular recognition in SLE patients and control subjects. However, it 
was unclear whether these two steps correspond to consecutive or simultaneous 
processes. QCM data can be used to determinate reaction kinetics [27]. For that and in 
order to understand the molecular recognition mechanism, a conformational dynamic 
study was performed either by a L1 and L2 norm minimization. The Akaike Information 
Criterion (AIC) was used to select the most suitable molecular mechanism for the 
TROVE2-autoantibodies interaction. The evolution of the piezoelectric signal according 
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to the reaction time was simultaneously modelled at different concentrations of anti-
TROVE2 autoantibody from SLE patients and healthy subjects (see Supplementary 
Tables 2 and 3). Considering the minimum AIC value (Figure 3), a two-step consecutive 
reaction model was proposed according to a bivalent recognition process for the 
autoantibodies. 
Figures 3a and 3b show a good agreement between the fitted and the experimental curves, 
confirming that the proposed binding schemes predicted correctly the TROVE2 
autoantibody binding within a wide range of autoantibody concentrations (see 
Supplementary Table 2). Experiments with increasing concentrations of autoantibodies 
fit to a first bimolecular association with a rate constant (kon1) and a dissociation rate 
constant (koff1) of around 1.1 L U
-1 s-1 and 6.8.103 s-1, respectively (see Supplementary 
Table 3). The second association constant (kon2) is 3.8
.104 s-1 and its corresponding 
dissociation constant (koff2) 8.2
.104 s-1, yielded a kinetic dissociation constant (Kd) of 9 U 
mL-1. According to these data, the affinity of anti-TROVE2 autoantibodies for TROVE2 
is high and practically independent of the hIgG source, suggesting that both epitopes must 





The main difference observed during the hIgG-TROVE2 binding between SLE patients 
and healthy subjects lies in the molecular weight of the involved antigenic complexes. 
Figure 3 shows how reaction products are always heavier than reaction intermediates, 
MWhIgG-TROVE2<MWcomplex. As mentioned above, this difference is due to autoantibody-
dependent modifications of the surrounding water that occurred during the biorecognition 
process. This is an important finding, since water is a major contributor to a protein's 
three-dimensional, 3D structure [28], and any change in the TROVE2 tertiary structure 
could occur during the TROVE2-autoantibody binding. 
More important structural changes in the surrounding water were observed in hIgGs of 
sera from SLE patients than in hIgGs from healthy subjects. A 
MWSLEpatients/MWhealthyubjects ratio of 1.8 was determined from QCM-D data. This ratio 
shows how the molecular weight of the antigenic complex composed of autoantibodies 
from SLE patients is almost twice that of the autoantibodies from control subjects. The 
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obtained results show how the conformational structure of the antigenic complexes is 
dependent on the origin of autoantibodies, facilitating the water motions and accelerate 
its hydration as appropriate. As the molecular weight of the autoantibodies is independent 
on the antibody origin, this result again corroborates a change in the TROVE2 tertiary 
structure during the TROVE2-autoantibody binding. Accordingly, Born et al. 
demonstrated that the water dynamics in a protein is controlled by its flexibility [29]. 
The mechanism proposed herein for the TROVE2-hIgG biorecognition takes place by a 
cooperative interaction. It is possible that these two steps were one Fab binding first and 
then the other Fab on the IgG or Fab binding followed by a Fc binding. We suggest that 
this process occurs via an antibody bipolar bridging mechanism, i.e., the antibody binds 
to the autoantigen through its Fab and concomitantly to a Fc binding site. To prove the 
model, and although Fc binding sites are not found on the TROVE2 (see Supplementary 
Figure 2), the results showed in Figure 4a demonstrated that the F(ab’)2 interaction 
involves conformational changes of TROVE2 that eventually expose specific sites to the 
Fc fragments of the autoantibodies. This is in agreement with the above change monitored 
during this recognition in the TROVE2 tertiary structure. Furthermore, the Fab fragments 
do not bind twice. Hence, we believe that this activation of the “hidden” Fc binding site 






The vWFA domain of the TROVE2 protein has a metal ion-dependent adhesion site 
(MIDAS) motif that binds to aspartate and in some cases to glutamate in a divalent cation-
dependent manner. Subsequently, this motif could be related to the binding chemistry of 
the TROVE2-autoantibody system. In order to investigate this chemical affinity, the 
influence of the divalent cation interaction (with a concentration of 100 mM) on the Fc-
binding affinity was studied. As is shown in Figure 4b the MIDAS motif acts as a high-
affinity Fc-receptor, and the affinity of TROVE2 for the Fc fragments increases as the 
ionic radii of the divalent cations increases; e.g. Mg2+ (x) < Ca2+ (1.3 x) < Sr2+ (2.3 x) < 
Ba2+ (10.5 x) (Figure 4b). Nonspecific interactions -negative binding controls- followed 
the opposite trend, Ba2+≈Sr2+ > Ca2+ = Mg2+ = 0, which agrees with the fact that the 
coordination geometry of this motif is close in size to the calcium cation. The MIDAS 
motif (diameter around 1.3 Å) of TROVE2 provides mainly a calcium coordination site 
(ionic radius 1.14 Å), being the Fc binding site exposed when the epitope-paratope 
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binding takes place. This finding supports the antibody bipolar bridging mechanism of 
TROVE2 and the autoantibodies. However, and as the MIDAS motif interacts with 
different divalent cations, it is important to emphasize that other divalent cations such as 
Mg2+, Ba2+ and Sr2+ might also affect the functional mechanism of the TROVE2 protein 
and consequently, any of these cations could be used in future treatments for autoimmune 
diseases. 
Therefore, the aforementioned results suggest that the MIDAS motif could act as a 
molecular switch capable of binding the autoantibody Fc fragment, depending on the 
alkaline earth cation present in solution. Hence, these ions could play a role of crucial 
importance in the immune signaling stimulus by intracellular antibody-bound pathogens, 
because its concentration changes during the cellular functions. 
Ro/SSA ribonucleoprotein complex 
Despite TRIM21 protein was initially proposed to be part of the Ro/SS-A 
ribonucleoprotein complex [8,19], the TRIM21-TROVE2 interaction remains unknown. 
Taking into account that the MIDAS domain has adhesive properties, we suggest that the 
TRIM21:TROVE2 association could be calcium-dependent. In order to test this 
hypothesis, the TRIM21-TROVE2 molecular recognition event was monitored in the 
presence (100 mM Ca2+) and absence of calcium cation. As is shown in Figure 4c, the 
interaction between both proteins without calcium reaches saturation at 122 ± 3.0 ng cm-
2. Nevertheless, the presence of calcium led to a similar value for the maximum signal 
(136 ± 3 ng cm-2) despite the TRIM21 concentration was decreased by 83% (from 300 
mg L-1 to 50 mg L-1). Furthermore, the time-dependent stability of this antigenic complex 
in PBS buffer was also studied. Figure 4c shows how the TRIM21-TROVE2 complex 
remains stable when the bulk calcium concentration is 100 mM whereas it is completely 
21 
 
dissociated when this bulk concentration is zero. Hence, the stability of this complex was 
higher when calcium ions were in the solution, indicating a weak interaction between the 
TRIM21 and TROVE2 proteins when the solution is free of this ion. 
As Figure 4c shows, the TRIM21-TROVE2 binding is a calcium-dependent interaction. 
Consequently, TRIM21 can be an integral part of the Ro/SS-A ribonucleoprotein complex 
depending on the calcium intracellular level. Subsequent studies failed to confirm the 
TRIM21-TROVE2 association [30,31] because the calcium concentration was not 
considered. Within a typical cell, the intracellular concentration of ionized calcium is 
roughly 100 nM, but that value is subject to increases of 10- to 100-fold during various 
cellular functions. In SLE patients, the cytoplasmic levels of TROVE2 antibodies, 
calcium, TRIM21 and TROVE2 are raised [32,33].Consequently, the link between all 
these species may be studied for a comprehensive understanding of the SLE disease. 
QCM-D data show how the TRIM21-antibody biorecognition does not occur when 
TRIM21 is blocked with TROVE2 (TRIM21 blocked with TROVE2 = blocked + antibody in solution ≈ 40 
ng/cm2, see Figure 4d). Nevertheless, TROVE2 is able to replace antibodies blocking the 
TRIM21 PRY-SPY domain (TRIM21 blocked with antibody = 450 ng/cm
2 >  blocked + TROVE2 in 
solution = 340 ng/cm
2, see Figure 4e). On the other hand, DPI results reveal how the 
TRIM21-TROVE2 bound involves a negligible change of thickness per molecule (0.47 
nm/molec.), because the TRIM21 protein may be in a flat-on manner on the sensor chip. 
According to these results, the TROVE2 protein should be placed between the two PRY-
SPRY domains, as shown in Figure 5a. All these experimental evidences confirm that 
TROVE2 and antibodies compete for the same binding site, being the affinity of the 
TRIM21 PRY-SPRY domain for TROVE2 higher than for autoantibodies (see Figures 
4d and 4e). Consequently, TROVE2 and the autoantibodies may have the same biological 
function regarding the TRIM21 protein. Therefore, the increase of the TROVE2 
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cytoplasmic level in SLE patients should stimulate the immune signaling via the TRIM21 
PRY-SPRY domain, such as intracellular antibody-bound pathogens provoke. 
All the previous data suggest that the Ro/SSA RNP complex formation depends on the 
TROVE2 and TRIM21 correlation levels. As Figure 5b shows, the serum levels of total 
anti-Ro/SSA RNP complex, anti-TRIM21 and anti-TROVE2 are correlated in most cases 
(n = 130, r = 0.72), being statistically significant (P < 0.0001). However, the level of anti-
TROVE2 subunit is the one that showed the highest influence, because the anti-TRIM21 
influence is minimal. Hence, the TROVE2 protein concentration is directly related to the 
concentration of the Ro/SSA RNP complex, while the coupling of TRIM21 with this 
complex may be singular depending at experimental conditions, corroborating our 






The autoantibodies bind TROVE2 via their Fab regions, thus, it is of utmost importance 
to identify the epitope region involved in the molecular recognition of the paratope. 
Several methods are available to epitope map [34,35]. However, we provide here one of 
the first practical applications of an innovative use of the QCM-D technique to map linear 
epitopes. For this purpose, the amino acid sequence of the TROVE2 protein (1-538 a.a) 
was mapped for hIgG-binding epitopes by testing 13 overlapping solid-phase synthetic 
polypeptides (see Figure 5c), using purified hIgGs from SLE and control sera. Figure 5a 
shows that the isolated hIgG proteins from SLE patients react strongly with polypeptides 
3, 4, 7, 10 and 12 while control sera react more efficiently with polypeptides 3, 4, 5, 7, 9 
and 12 (see numeric code in Supplementary Table 4). These results confirm that there are 
no substantial differences in affinity between SLE and control purified hIgGs. In addition, 
the obtained results also point out the fact that both epitopes must be structurally similar. 
However, Figure 5c shows how SLE hIgGs target an epitope more localized than the 
control hIgGs. Understandably, this specific immunity may be acquired naturally by an 
increase of exposure to antigen in SLE patients. Accordingly, T cells from SLE patients 
show an increased necrosis as compared with normal T cells [36]. 
In addition, Figure 5c shows the location of these epitopes within the overall autoantigen 
domain organization. The region composed by polypeptides 3-5 (80-210 aa) matches with 
the YRNA binding surface (142-149 and 176-187 aa), so that Fab fragments of anti-
TROVE2 autoantibodies may block the YRNA binding, according to Stein et al.[12] As 
a result, it might be concluded that the Fab fragments, during the epitope-paratope 
binding, should cover the TROVE domain toroidal cavity preventing the single stranded 
RNA binding, particularly in SLE patients. However, it remains unclear whether the 
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autoantibodies against intracellular functional domains are able to influence biological 
function in vivo. 
On the other hand, Fc fragments interact with the vWFA domain of platelet membrane 
receptors.[37] For the first time, the QCM-D technique has been used for the first time to 
map Fc-receptors in the protein tertiary structures. We found Fc interaction with 
polypeptides 7 and 8 (240-330 a.a., Figure 5c). Our results thus suggest that this region 
may be a hidden second Fc binding site in TROVE2. Considering the typical antibody 
dimensions, (10 nm long, 10-15 nm high and 2.5 deep), this binding site cannot be 
involved in the proposed antibody bridging mechanism as the distance between this Fc 
binding site and the found epitope is about 4 nm. Hence, this hidden second Fc may only 
facilitate the formation of the TROVE2 cross-linked autoantibody aggregates. 
 
DISCUSSION 
In this study, we have elucidated the binding mechanism of the TROVE2 biological 
system in SLE patients and healthy subjects by performing basic in vitro and theoretical 
assays. Thus, a novel application of the QCM-D and DPI techniques has shown new 
insights in the mechanism of self-recognition of the autoantigen TROVE2. The 
circulating anti-TROVE2 autoantibodies are likely to either undergo “autoantibody 
bipolar bridging” or simultaneous binding of the autoantigen TROVE2 to both Fab and 
Fc domains. Epitope mapping revealed that anti-TROVE2 autoantibodies unambiguously 
block the YRNA binding as well as that SLE patients have an increase in specific 
immunity due to higher exposure to antigen. 
In addition to the vWFA domain, a new Fc binding site hidden in the TROVE2 tertiary 
structure was found, which facilitates the formation of TROVE2 cross-linked 
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autoantibody aggregates. Consequently, anti-TROVE2 autoantibodies that undergo 
TROVE2-mediated bipolar bridging, resulted in their cross-linking and a similar block to 
Fcγ receptor and complement interaction. TROVE2-mediated bipolar bridging can occur 
by a single IgG bound by a single TROVE2 molecule, or, more likely, one TROVE2 
molecule interacting with an anti-TROVE2 autoantibody; that is, bound by the discovered 
hidden Fc binding site of a second TROVE2 molecule. As the TROVE2 levels increase 
in SLE patients, it is likely that the resulting cross-linked bipolar-bridged immune 
complexes form very large protein aggregates. 
Autoantibody bipolar bridging could affect autoimmune pathogenesis in several ways. 
First, bipolar-bridged complexes might contribute to the pathogenic deposition of 
immune complex in SLE because these large aggregates would not be cleared from the 
serum of SLE patients. Second, bipolar-bridged autoantibodies associated with TROVE2 
on the surface of apoptosing cells could inhibit cell clearance, for example by blocking 
access to so-called ‘‘eat me’’ signals on the cell surface [38].This hypothesis could 
explain the defective clearance of apoptosed cells observed in diseased SLE mice [39]. 
Furthermore, we have demonstrated that probably subsequent studies failed to confirm 
the TRIM21-TROVE2 association because the intracellular calcium level was not 
considered. This binding might occur by means of calcium dependent protein-protein 
bridges, being located in the TRIM21 PRY-SPRY domain. Accordingly, the calcium-
dependent association of TRIM21 with TROVE2 might mediate an inflammatory 
response in SLE patients through the intracellular immune signaling activated by this 
TRIM21 PRY-SPRY domain, affecting autoimmune pathogenesis. Furthermore, this 
discovery links the intracellular immune response against antibody-coated viruses, 
bacteria or prions (TRIM21 protein) with the stabilization and protection from 
degradation of non-coding RNAs, pre-5S rRNA, and several small cytoplasmic RNA 
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molecules known as Y RNAs (TROVE2 protein), which represents a paradigm shift in 
how we think about viral immunity. 
Given the pathogenic role of TROVE2 in systemic autoimmunity, these findings provide 
new insights into the pathogenesis of SLE disease. As a result, our findings might explain 
better the regulation of the TROVE2 physiological function and consequently, this 
information may be of utmost for understanding SLE disease. We believe that the 
mechanism we unrevealed may have potential applications in the design of new therapies 
for SLE. Finally, the novel methodology to analyze data of QCM-D and DPI applied here 
facilitates new insights in mechanisms of protein-protein interactions. 
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Figure 2.- Response of the TROVE2-based biosensors with respect to: a) -∂f/∂D ratio for IgG from sera of 
SLE patients ([SLE hIgG] = 18.91 U/mL, left) and healthy subjects ([control hIgG] = 12.39 U/mL, right). b) 
DPI values of thickness per molecule monitored during the hIgGs:TROVE2 biorecognition for SLE patients 
(left and black, [SLE hIgG] = 4.43 U/mL) and healthy subjects (right and blue, [control hIgG] = 15.48 U/mL). 
The antibody structures show the theoretical thicknesses per molecule of different orientations of the antibody 










Figure 3.- Real time relaxation curves (ΔΓ evolution as function of time) of the hIgG-TROVE2 
interaction for different antibody concentrations obtained from sera of a) SLE patients and b) healthy 
subjects. Red lines are the fittings from the kinetic parameters shown on the reaction mechanism. 





Figure 4.- a) Detection of Fc fragments by the TROVE2 protein previous (blue), or not (green), 
interaction with F(ab’)2 fragments. b) Influence of the ionic radii of alkaline earth ions in the detection 
of Fc fragments. Red line represents the nonspecific interactions with BSA. c) TRIM21-TROVE2 
interaction in presence ([TRIM21α] = 50 mg/L, blue) and absence ([TRIM21α] = 300 mg/L, black) of 
calcium ions. d) Antibody biorecognition (12.5 U/mL) by TRIM21 previously blocked with TROVE2. 







Figure 5.- a) The TRIM21-TROVE2 binding scheme. b) Correlation for serum levels of anti-TROVE2 and anti-
TRIM21 with levels of anti-Ro (full complex). c) Interaction of different TROVE2 polypeptides (see numeric code in 
Supplementary Table 4) with hIgGs obtained from SLE patients and healthy subjects as well as with Fc fragments. The 
binding sites are localized in the TROVE2 tertiary structure with the same color code than the corresponding bar chart. 
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